Please assess the completion status of the following clinical trial:

Trial Title: Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Ages eligible for study : 18 years to 74 years~* Genders eligible for study : Male and Female~* Diagnosed with T2DM~* Taking a stable dose of metformin monotherapy~* HbA1c levels of between ≥ 7.0% and ≤ 10.0%~* Females of childbearing potential who are not pregnant and agree to use a reliable method of birth control~* Written informed consent must be obtained~Exclusion Criteria:~* Pregnant or nursing (lactating) women~* Diagnosis of type 1 diabetes mellitus~* Uncontrolled diabetes defined as a FPG level of \> 240 mg/dL at screening~* A significant change in body weight in the 3 months before screening~* Any history of GI intolerance~* Personal or family history of medullary thyroid cancer (MTC) or a genetic condition that predisposes to MTC~* Known history of acute or chronic pancreatitis~* A history of alcohol or drug abuse or drug addiction

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- HM11260C (8 mg) (Type: EXPERIMENTAL): Monthly administration of 8 mg of HMC11260C by subcutaneous injection for 16 weeks
- HM11260C (12 mg) (Type: EXPERIMENTAL): Monthly administration of 12 mg of HMC11260C by subcutaneous injection for 16 weeks
- HM11260C (16 mg) (Type: EXPERIMENTAL): Monthly administration of 16 mg of HMC11260C by subcutaneous injection for 16 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Monthly administration of placebo by subcutaneous injection for 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).